A milestone review examining 1.4 million patients worldwide found that those who do not see the same doctor regularly are ...

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...

The Shepherd’s Center of Greater Winston-Salem is offering a workshop for individuals turning 65 (as well as those who ...

The average life expectancy of people diagnosed with dementia ranges from nine years at age 60 to 4.5 years at age 85 for ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Previous research has associated sleep medications with other health risks, such as falls, fractures, car accidents, and ...

First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer ...

HONG KONG, Jan 6 (Reuters) - China has launched a national plan to address the rapidly growing prevalence of dementia, which authorities say is becoming "a widespread societal concern" and poses ...

The challenge is how to reliably harness those "digital indicators" to inform the development of new dementia drugs. The move comes as the first approved drug for Alzheimer's – Biogen and Eisai ...

Impairment in language is a common finding among individuals with dementia and can be a presenting symptom, particularly in Alzheimer's dementia and primary progressive aphasia. Early recognition ...